|
gptkbp:instanceOf
|
gptkb:synthetic_cannabinoid
|
|
gptkbp:actsOn
|
CB1 receptor agonist
CB2 receptor agonist
|
|
gptkbp:CASNumber
|
209414-07-3
|
|
gptkbp:category
|
gptkb:recreational_drug
gptkb:naphthoylindole
gptkb:synthetic_cannabinoid
CB1 receptor agonist
CB2 receptor agonist
|
|
gptkbp:chemicalFormula
|
C24H23NO
|
|
gptkbp:discoveredBy
|
gptkb:John_W._Huffman
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:firstSynthesized
|
1995
|
|
gptkbp:hasSMILES
|
CCCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43
|
|
gptkbp:IUPACName
|
1-pentyl-3-(1-naphthoyl)indole
|
|
gptkbp:legalStatus
|
illegal in many countries
Schedule I controlled substance in the United States
Class B drug in the United Kingdom
|
|
gptkbp:marketedAs
|
gptkb:spice
K2
|
|
gptkbp:meltingPoint
|
162–166 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
341.45 g/mol
|
|
gptkbp:namedAfter
|
gptkb:John_W._Huffman
|
|
gptkbp:PubChem_CID
|
20941407
|
|
gptkbp:relatedTo
|
gptkb:HU-210
gptkb:JWH-073
gptkb:JWH-122
gptkb:AM-2201
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
|
|
gptkbp:sideEffect
|
nausea
vomiting
anxiety
hypertension
paranoia
psychosis
seizures
tachycardia
hallucinations
agitation
|
|
gptkbp:UNII
|
K2CYN6F2V5
|
|
gptkbp:used_in
|
herbal incense blends
|
|
gptkbp:usedFor
|
gptkb:recreational_drug
research chemical
|
|
gptkbp:bfsParent
|
gptkb:JWH_cannabinoids
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
JWH-018
|